OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI agent that can act

Oracle stock took off as President Trump announced the Stargate AI infrastructure project. Read why I maintain my buy rating for ORCL stock.

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure cancer. We’ve all heard such blusterous aspirational hype before, to be sure.

Key Takeaways Nuclear energy stocks roared higher Thursday, extending gains earlier in the week amid expectations of growing energy needs driven by data centers to support AI.President Donald Trump on Tuesday announced a $500 billion joint venture with Oracle,

President Trump on Tuesday announced a $500 joint venture with Oracle, OpenAI, and SoftBank to build AI infrastructure in the U.S.

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

OpenAI is taking steps to transform its AI-powered chatbots into autonomous software engineers, aiming to redefine the future of artificial general intelligence, according to The Information.

Oracle stock jumped 6% on a report that Trump plans to announce billions of dollars in private sector investment to build artificial intelligence infrastructure in the US.

Tesla (TSLA) and SpaceX CEO Elon Musk said OpenAI, Oracle (ORCL) and Softbank (SFTBY) “don’t actually have the money” to back up their pledge

Altman and Musk were OpenAI’s founding co-chairs in 2015, but their relationship has devolved into name-calling and lawsuits.

The feud between Elon Musk and Sam Altman has been years in the making, litigious, and above all else, personal. Or at least it used to be. Now Musk is holding Altman’s feet to the fire for his wavering loyalties to President Donald Trump.